Login or Register

About the Foundation

Dr. Ianchulev, President of the KeepYourSight Foundation
Dr. Ianchulev, Clinical Associate Professor, UCSF

The KeepYourSight Foundation has one simple vision – helping everyone else keep theirs. KeepYourSight has launched an unprecedented e-health initiative in the fight against blindness - by investing in breakthrough telemedicine technology and using the broad platform of the Internet, KeepYourSight is bringing public health outreach and blindness prevention to everyone’s home... for free

The KeepYourSight Mission
Two eye doctors – one mission: Keep Your Sight!

The original idea behind KeepYourSight and online vision screening started in 2005 when two eye doctors realized that many of their patients were going blind even before they reached the clinic. Despite a busy practice, Drs. Ianchulev and Pham set out on a mission to solve a problem of public health proportions for both developed and under-developed countries alike where more than 50% of all glaucoma remains undiagnosed - in the US more than 1.5-2 million people are losing sight to glaucoma without notice.

In 2006, Drs. Ianchulev and Pham developed the first prototype of the visual field test, called Peristat, which can deliver an online adaptation of the clinical perimetry test used in specialized medical offices. It took years to perfect and improve the prototype to allow efficient and streamlined testing. Today the Peristat test can be taken virtually from any internet computer and in less than 5 minutes. Focused on how to improve public health further, Drs. Ianchulev and Pham added another telemonitoring test called Macustat for retinal function testing. Macustat is a 3 minute online test for the early detection of retinal problems such as AMD and diabetic retinopathy.

In 2010, Dr. Ianchulev and Pham started the KeepYourSight charitable foundation to further the work on a larger scale and help millions of people worldwide keep their sight

To read a brief bio of Dr. Ianchulev and Dr. Pham, click here >>

Approach to solving problem: Screening and Telemedicine and technology

After years of research and development, KeepYourSight has launched a new vision screening system. The two online tests Peristat and Macustat target the two leading causes of preventable blindness in the world – glaucoma and macular degeneration. The KYS vision screening system is the first true telemedicine platform which allows people to transform their home computer into a virtual public health terminal and test themselves on their own and in real time! No need for expensive equipment, computer peripherals or special devices – simply a computer with a browser connected to the Internet.

The KeepYourSight approach is unique – it uses the power of online technology, telemedicine and real-time connectivity to solve one of the biggest challenges for any public health program – scalability, universal access and high throughput screening. By placing cutting edge medical technology online at everyone’s fingertips the KYS Foundation is not only raising awareness but delivering measureable results for public eye health and patients worldwide.

KYS Approach: Free Online Vision Testing any place, any time by everyone!


Dr. Ianchulev, Clinical Associate Professor, UCSF

Dr. Ianchulev is a Harvard trained physician-ophthalmologist with continued interest in the global problems of public health. During his medical training in Boston, his passion lead him to the Harvard School of Public Health where he appreciated the need for global outreach and self-sustained health initiatives through technology and innovation.

Since then, Dr. Ianchulev has been on the cutting edge of innovation in health care, making an impact in the treatment of major eye diseases such as macular degeneration and glaucoma. As the director of the Genentech clinical eye research, he was instrumental in the development and launch of Lucentis - the most impactful therapy in ophthalmology and the first antibody treatment for an eye disease. Dr. Ianchulev is also leading the development efforts for minimally invasive glaucoma surgery with one of the first microstents in FDA studies.

More importantly, Dr. Ianchulev travels throughout the world and does missionary work as a cataract and glaucoma surgeon in countries where people have little or no access to surgical care.

Dr. Ianchulev is an Associate Clinical Professor at UCSF and a fellow of the American Academy of Ophthalmology.

Dr. Peter Pham, Co-Founder, Secretary

Dr. Pham is a boarded certified ophthalmologist who has devoted his professional life to restoring sight and helping patients keep their vision. As a surgeon and clinician, Dr. Pham treats blinding conditions such as glaucoma, cataract and macular degeneration. As a researcher, he worked on the development of a novel delivery system for introducing large-sized molecular compounds into thousands of living cells simultaneously. These molecular compounds allowed researchers to trace the molecular process cells use to achieve cellular movement, which is a critical biological task in everything from bone growth to cancer metastasis. Realizing the importance of technology and innovation for screening and prevention, Dr. Pham teamed up with Dr. Ianchulev to develop the KeepYourSight online telemedicine system for vision health.

Dr. Pham received his medical degree from Washington University School of Medicine in St. Louis after graduating summa cum laude from Washington University with an undergraduate degree in chemistry. He completed his ophthalmology training at the Doheny Eye Institute in Los Angeles. Dr. Pham is the Chief of Surgery at St. Luke’s Hospital at the Vintage and maintains an active ophthalmology practice in the Houston area.

Dr. Curt LaBelle, Director

Dr. LaBelle has spent his career identifying and developing medical products that address major clinical needs. As a physician business executive, he has unique expertise that bridges medicine, finance and technology innovation. He has more than a decade long experience in healthcare growth and venture capital and has been a catalyst to many therapeutic advances in medicine. He has served as a board member or observer with numerous health care companies, including Adams, Adiana, Aldagen, Coherex, Impulse Monitoring, KAI Pharmaceuticals, Myocor, and Sirion Therapeutics. In addition to his current role as a partner with Tullis Health Investors, Dr. LaBelle has worked as a Vice President at Investor Growth Capital, Inc., a global private equity firm with over $1 billion under management, and with Pfizer in outcomes research and marketing.

Dr. LaBelle holds MD and MBA degrees from Columbia University.

Dr. Robert Stamper, UCSF

Dr. Robert L. Stamper is Professor of Clinical Ophthalmology at the University of California, San Francisco, School of Medicine. In addition, he is the Director of the Glaucoma Service in the Department of Ophthalmology there. He was Director of the Glaucoma Service at California Pacific Medical Center for over 25 years and served as the chairman of the Department of Ophthalmology there from 1987-1995.

Dr. Stamper has given numerous presentations at both national and international conferences and society meetings – most recently as visiting professor in Venezuela, Peru, New Zealand, Harvard, Washington University St. Louis and Yale. He is the senior author of the 7th and 8th editions of Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Dr. Stamper is also the recipient of many awards and honors, including being listed in the Best Doctors in America six times, Who’s Who in America and Who’s Who in the World. He has received the Lifetime Achievement Award of the American Academy of Ophthalmology in 1908. He has published over 85 peer-reviewed articles and has served on the editorial or review boards of the AJO, Archives, Ophthalmology, IOVS, British Journal of Ophthalmology, Eye Research, and Cataract and Refractive Surgery. His memberships include the American Academy of Ophthalmology, the American Ophthalmologic Society, the Glaucoma Society of the International Congress of Ophthalmology and the American Glaucoma Society of which he was the president in 1999-2000. Dr. Stamper was the American Glaucoma Society’s guest of honor at their 25th anniversary meeting. He is a past Director of the American Board of Ophthalmology. He served for over 25 years with the Joint Commission on Allied Health Personnel in Ophthalmology, was its President in 1984-5, and received the Statesmanship Award in 1989. He is also the recipient of the Troutman Master Teacher award and the Kimura Teaching award.

Dr. Donald Minckler, UCI

Dr. Minckler is a Professor of Ophthalmology and Ocular Pathology at the University of California, Irvine. He is a distinguished glaucoma specialist, surgeon and academician who is well published in the field of ophthalmology. Dr. Minckler is one of the few physicians with dual board certification in ophthalmology and pathology. In addition, he has held many leadership positions in the field, including editor-in-chief of the prestigious Journal “Ophthalmology”, as well as director of the American Board of Ophthalmology. His principal research interests have been the pathophysiology of optic nerve injury in glaucoma and advanced surgical treatment options for glaucoma including aqueous shunt implants.

Dr. Pamela M. Klein

Dr. Klein is a medical oncologist with strong expertise in drug development. She currently serves as an advisor/consultant on strategy and drug development to all stages of biotechnology and Pharma companies. She is also an expert advisor to several Venture Capital firms. Most recently, Dr Klein was CMO for Intellikine, where she built and led the clinical development organization enabling several first in man studies. Previous to this, Dr. Klein was Vice President, Development, Genentech where she led the development of a large portfolio of drugs including drugs like Herceptin that have changed the way breast cancer is treated. Prior to Genentech, Dr. Klein spent 7 years at the National Cancer Institute, where she built and developed the NCI-Navy Breast Care Center, serving as Research Director for the Center. Aside from her day job, Dr. Klein’s passions is global health care and she has spent time involved in outreach projects in Eastern Europe, the Peruvian Amazon and the Middle East both treating and educating fellow health care providers. Klein later earned her medical degree from Stritch School of Medicine, Loyola University and completed her internal medicine residency training at Cedar-Sinai Hospital where she received the Leo Rigler Award for Resident of the Year, and the Ben Newman Award for the Most Humanistic Physician. She did a Medical Oncology Fellowship at the National Cancer Institute serving as Chief Fellow from 1995 – 1996, and then went on to complete an advanced research fellowship within the Department of Genetics.

Dr. Adrienne Graves

Dr. Graves is a preeminent global business leader in the ophthalmic field. As the past CEO of Santen-US, a subsidiary of a 120-year old Japanese pharmaceutical company, she has successfully spearheaded product innovation for the benefit of vision care and patients worldwide. At the same time, ensuring strong commercial leadership and turn-around performance for the company, while building an organization of operational excellence. Dr. Graves has forged global partnerships at clinical, scientific, corporate and board levels and brought multiple early pharmaceutical agents through clinical trials to commercialization.

Dr. Graves is known as a transformational leader who has guided global teams on successful acquisitions and partnerships. She is a dynamic, highly sought-after international speaker on topics of leadership development, scientific careers, women's leadership/mentoring, and scientific and business development. Dr. Graves is on the board of key organizations such as the American Society for Cataract & Refractive Surgery Foundation, the Glaucoma Research Foundation, the Foundation of the American Academy of Ophthalmology, the Pan-American Ophthalmological Foundation and others.

Dr. Graves received her PhD in Psychobiology from the University of Michigan, Ann Arbor, and did her Postdoctoral Fellowship in Visual Neuroscience at the University of Paris. She received her AB with Honors in Psychology from Brown University in Providence, Rhode Island.

Dr. Sonia Yoo

Dr. Yoo is a Professor of Ophthalmology and Biomedical Engineering at the renowned Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. Dr. Yoo is a prominent ophthalmic surgeon with a specialty focus on the cornea, cataract and refractive surgery. Dr. Yoo is well known in the academic field as an innovator and progressive clinical scientist whose works are on the forefront in the ophthalmic field with over 100 book chapters and peer-reviewed journal articles.

As a prominent clinician, Dr. Yoo plays a leadership role on boards and committees of key professional organizations in the ophthalmic field, including the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery, and the American Board of Ophthalmology. She is a reviewer for scientific journals such as the Archives of Ophthalmology, Ophthalmic Surgery, Lasers and Imaging, Cornea, Journal of Cataract and Refractive Surgery, Journal of Refractive Surgery and Ophthalmology, and others.

Dr. Thom Zimmerman (posthumous)

Thom J. Zimmerman, MD, PhD, was an ophthalmologist and an ocular pharmacologist. He was department chair at Ochsner Clinic in New Orlelans and at the University of Louisville. He was also the Global Ophthalmic Medical Director for Pharmacia, and then Pfizer, Inc. On the research side, Thom has spearheaded one of the most impactful innovations in the field of glaucoma – as the developer behind Timolol, the mainstay of glaucoma therapy, Thom has made a tremendous difference for vision worldwide.

Thom is the recipient of many honors and awards for his contribution to the field of glaucoma: Alpha Omega Alpha, University of Illinois School of Medicine, Heed Ophthalmic Foundation Fellowship, Robert E. McCormick Scholar, Research to Prevent Blindness , The Sir Duke Elder Award of the International Glaucoma Congress, Prevent Blindness America Foundation, Parke Lewis Founders Award. Thom also served on many editorial boards including the Annals of Ophthalmology, the Journal of Ocular Therapy and Surgery,the American Journal of Ophthalmology, the Archives of Ophthalmology, and more. In addition, he published nearly 350 scholarly papers and wrote or co-wrote more than a dozen books.

Thom was one of the original thought leaders and scientific partners behind the KeepyourSight initiative. A staunch proponent of glaucoma screening and prevention, Thom was instrumental in helping the KeepYourSight team develop the technology and shepherd it through to fruition. KeepYourSight would like to acknowledge Thom for his invaluable contribution and the legacy he leaves behind for the benefit of patients worldwide.

Colin O'Donnell, MBA

Colin O'Donnell is a Managing Partner/Chief Investment Officer (CIO) at Minetta Lane Investments. Prior to Minetta Lane, Colin held senior positions at a number of premier financial and investment banking institutions including Steadfast, a $3b+ AUM investment fund, GMAC Commercial Capital where he co-founded a merchant bank in 2002 and Credit Suisse First Boston. Colin holds a BS in International Politics and Economics from Georgetown University's School of Foreign Service.

Testimonials: How KeepYourSight can make a difference…

Kathy Bailey, Patient with Glaucoma

“KeepYourSight and Dr. Ianchulev helped me stay ahead of my glaucoma ….
I was lucky to be one of the first people to use the online Peristat visual field screening test when the service first became available. …”
If I had had access to the KeepYourSight service before I first started experiencing symptoms, I could have avoided four years of serious eye problems and could have saved the vision in my left eye. I fully subscribe to the mission of KeepYourSight and admire Dr Ianchulev’s dedication for bringing free vision screening to the world.

Doctor: Dr. Minckler, Professor University of California Irvine

“Degenerative eye diseases such as glaucoma rarely have symptoms early in their course. Screening and prevention are important for those at risk – particularly people over 50 years of age. The ability to empower people to check themselves at home is a major step forward in our fight against this blinding disease….”

Dr. Koo : Associate Professor UCSF

“We are a busy ophthalmology practice in the Bay Area. As eye doctors, we encourage our patients to use KeepYourSight for free vision testing for themselves, their families and friends. This is a wonderful tool for monitoring and early detection in between visits to the office. This is a great cause – and truly remarkable how the Internet can be so transformational and allow unprecedented outreach and access. “

Patient with advanced glaucoma:

[In consultation with Dr. Ianchulev] Below is one of Dr. Ianchulev’s many patient stories who are at the core of KeepYourSight’s mission. A 56 year old man had unsuspected glaucoma for many years before finally seeing the eye doctor. He had no symptoms and was able to read the newspaper and watch TV. Yet, he was legally blind with little peripheral vision left. Most of his visual field had been destroyed by glaucoma – one of the leading causes of blindness for people over 50. With KeepYourSight, such visual field defects can be detected early, sometimes years before it is too late…...Below you can see how the online Peristat test can easily detect the visual defect – similar to the sophisticated office technology available only in specialized clinics and hospitals.

Large blind spots and defect in the peripheral vision can go unnoticed for years. Visual field testing is essential for early detection and screening...

Conventional In-Office Visual Field Test

Visual Field Test
Peristat Online Visual Field Test

Visual Field Test
The black corresponds to the area of visual field loss. The patient has lost the entire upper half of their visual field without seeing any problems . Both the office and the online Peristat test can easily detect the damage even if the patient is unaware.